StrandID
June 25, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Diagnostics and Personalized Medicine
StrandID is building a universal genome detection platform designed to integrate into point-of-care diagnostic kits. Our technology uses computationally designed DNA probes that bind cooperatively across pathogen genomes, generating visible signals on a lateral flow strip without instruments, power, or training. Results are delivered in rapidly, with foundational research demonstrating sensitivity of 5 genomic copies/mL. Partners develop the sample preparation; our device detects the target. Probe sets can be generated computationally within hours, enabling partners to rapidly expand their test menus. StrandID is advancing STRAND toward commercialization through a manufacturing partnership with Abingdon Health, a leading lateral flow CDMO.
Company HQ City:
Menlo Park
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2026
CEO
Minsung Cho
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}